Stefan Sleijfer

28.5k citations

380 papers · 13.8k · 2 hit papers · h-index 61

Impact in

Oncology top 0.1%
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Vascular Tumors and Angiosarcomas
Cancer Research top 0.2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 142
- Cancer Cells and Metastasis 38
- Cancer Immunotherapy and Biomarkers 22
- CAR-T cell therapy research 17
- Colorectal Cancer Treatments and Studies 16
Pulmonary and Respiratory Medicine 116
- Sarcoma Diagnosis and Treatment 52
- Renal cell carcinoma treatment 20

Co-authors: Jaap Verweij (37 shared papers)John A. Foekens (47 shared papers)John W.M. Martens (82 shared papers)Jan W. Gratama (26 shared papers)Reno Debets (29 shared papers)C. B. H. W. Lamers (25 shared papers)Anieta M. Sieuwerts (44 shared papers)Agnes Jager (37 shared papers)
Journals: Journal of Clinical Oncology (30 papers)European Journal of Cancer (27 papers)Annals of Oncology (20 papers)British Journal of Cancer (20 papers)Molecular Oncology (14 papers)
Partner nations: Netherlands Belgium United States

In The Last Decade

Stefan Sleijfer

376 papers receiving 13.6k citations

Stefan Sleijfer's Hit Papers

align trajectories log scale

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity 2013 · 577 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Molecular Therapy
2009 Journal of Clinical Oncology

Peers

Countries citing papers authored by Stefan Sleijfer

Since Specialization

Citations

This map shows the geographic impact of Stefan Sleijfer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Sleijfer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Sleijfer more than expected).

Fields of papers citing papers by Stefan Sleijfer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Sleijfer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Sleijfer. The network helps show where Stefan Sleijfer may publish in the future.

Co-authors

The 25 scholars most cited alongside Stefan Sleijfer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stefan Sleijfer Line = papers co-authored together Stefan Sleijfer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 380 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity Molecular Therapy ·C. B. H. W. Lamers, Stefan Sleijfer, Sabine van Steenbergen, Pascal van Elzakker, Brigitte van Krimpen, C.A.M. van der Velden-de Groot, Arnold G. Vulto, Michael den Bakker, Egbert Oosterwijk, Reno Debets, Jan W. Gratama Hit paper breakdown →	2013	577
2	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) Journal of Clinical Oncology ·Stefan Sleijfer, Isabelle Ray‐Coquard, Zsuzsa Pápai, Axel Le Cesne, Michelle Scurr, Patrick Schöffski, Françoise Collin, Lini Pandite, Sandrine Marréaud, Annick De Brauwer, M. van Glabbeke, Jaap Verweij, Jean‐Yves Blay Hit paper breakdown →	2009	540
3	Bleomycin-Induced Pneumonitis CHEST Journal ·Stefan Sleijfer	2001	423
4	Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells Blood ·C. B. H. W. Lamers, Ralph A. Willemsen, Pascal van Elzakker, Sabine van Steenbergen‐Langeveld, Marieke Broertjes, Jeannette Oosterwijk‐Wakka, Egbert Oosterwijk, Stefan Sleijfer, Reno Debets, Jan W. Gratama	2010	293
5	Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer Cancer Treatment Reviews ·Bianca Mostert, Stefan Sleijfer, John A. Foekens, Jan W. Gratama	2009	232
6	Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels Hypertension ·Mariëtte H.W. Kappers, Joep H.M. van Esch, Wim J. Sluiter, Stefan Sleijfer, A.H. Jan Danser, Anton H. van den Meiracker	2010	224
7	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies Nature Genetics ·Lindsay Angus, Marcel Smid, Saskia M. Wilting, Job van Riet, Arne van Hoeck, Luan Nguyen, Serena Nik‐Zainal, Tessa G. Steenbruggen, Vivianne C. G. Tjan‐Heijnen, Mariëtte Labots, J.M.G.H. van Riel, Haiko J. Bloemendal, Neeltje Steeghs, Martijn P. Lolkema, Emile E. Voest, Harmen J.G. van de Werken, Agnes Jager, Edwin Cuppen, Stefan Sleijfer, John W.M. Martens	2019	207
8	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas European Journal of Cancer ·Stefan Sleijfer, M. Ouali, M. van Glabbeke, Anders Krarup‐Hansen, Sjoerd Rodenhuis, Axel Le Cesne, Pancras C.W. Hogendoorn, Jaap Verweij, Jean‐Yves Blay	2009	199
9	Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells European Urology ·Wendy Onstenk, Anieta M. Sieuwerts, Jaco Kraan, Mai N. Van, Annemieke J.M. Nieuweboer, Ron H.J. Mathijssen, Paul Hamberg, Hielke J. Meulenbeld, Bram De Laere, Luc Dirix, Robert J. van Soest, Martijn P. Lolkema, John W.M. Martens, Wytske M. van Weerden, Guido Jenster, John A. Foekens, Ronald de Wit, Stefan Sleijfer	2015	197
10	Side Effects of Interferon-α Therapy Pharmacy World & Science ·Stefan Sleijfer, M. Bannink, Arthur R. Van Gool, Wim H.J. Kruit, G. Stoter	2005	196
11	Circulating Tumor Cell Isolation and Diagnostics: Toward Routine Clinical Use Cancer Research ·Anja van de Stolpe, Klaus Pantel, Stefan Sleijfer, Leon W.M.M. Terstappen, Jaap M. J. den Toonder	2011	180
12	The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature The Oncologist ·Hánah N. Rier, Agnes Jager, Stefan Sleijfer, Andrea B. Maier, Mark‐David Levin	2016	165
13	Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR Breast Cancer Research and Treatment ·Anieta M. Sieuwerts, Jaco Kraan, Joan Bolt‐de Vries, Petra van der Spoel, Bianca Mostert, John W.M. Martens, Jan‐Willem Gratama, Stefan Sleijfer, John A. Foekens	2008	145
14	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies Cancer Treatment Reviews ·Kostandinos Sideras, Henri Braat, Jaap Kwekkeboom, Casper H.J. van Eijck, Maikel P. Peppelenbosch, Stefan Sleijfer, Marco J. Bruno	2013	142
15	Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response Clinical Cancer Research ·Jozien Helleman, Maurice P.H.M. Jansen, Kirsten Ruigrok-Ritstier, Iris L. van Staveren, Maxime P. Look, Marion E. Meijer‐van Gelder, Anieta M. Sieuwerts, Jan G.M. Klijn, Stefan Sleijfer, John A. Foekens, Els M.J.J. Berns	2008	142
16	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis Acta Oncologica ·Attila Kollár, Robin L. Jones, Silvia Stacchiotti, Hans Gelderblom, Michele Guida, Giovanni Grignani, Neeltje Steeghs, Akmal Safwat, Daniela Katz, Florence Duffaud, Stefan Sleijfer, Winette T.A. van der Graaf, Nathan Touati, Saskia Litière, Sandrine Marréaud, Alessandro Gronchi, Bernd Kasper	2016	140
17	Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overview Biochemical Society Transactions ·C. B. H. W. Lamers, Yarne Klaver, Jan W. Gratama, Stefan Sleijfer, Reno Debets	2016	134
18	(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor The Oncologist ·Paul Hamberg, Jaap Verweij, Stefan Sleijfer	2010	125
19	Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy The Breast ·Hánah N. Rier, Agnes Jager, Stefan Sleijfer, Joost van Rosmalen, Marc C. J. M. Kock, Mark‐David Levin	2016	124
20	Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions Molecular Oncology ·Lisanne F. van Dessel, Nick Beije, Jean Helmijr, Silvia Rita Vitale, Jaco Kraan, Maxime P. Look, Ronald de Wit, Stefan Sleijfer, Maurice P.H.M. Jansen, John W.M. Martens, Martijn P. Lolkema	2017	120

About Stefan Sleijfer

Stefan Sleijfer is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 380 papers that have together received 13.8k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (69 papers), Sarcoma Diagnosis and Treatment (52 papers), Cancer Cells and Metastasis (38 papers), Gastrointestinal Tumor Research and Treatment (32 papers), Cancer Immunotherapy and Biomarkers (22 papers), Renal cell carcinoma treatment (20 papers), CAR-T cell therapy research (17 papers) and Colorectal Cancer Treatments and Studies (16 papers). The work is most often cited by research in Oncology (5.9k citations), Cancer Research (2.9k citations), Pulmonary and Respiratory Medicine (3.7k citations), Gastroenterology (393 citations) and Immunology (1.3k citations). Stefan Sleijfer has collaborated with scholars based in Netherlands, Belgium and United States. Frequent co-authors include Jaap Verweij, John A. Foekens, John W.M. Martens, Jan W. Gratama, Reno Debets, C. B. H. W. Lamers, Anieta M. Sieuwerts, Agnes Jager, Jaco Kraan and Bianca Mostert. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, British Journal of Cancer and Molecular Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Stefan Sleijfer

Impact in

Papers in i

In The Last Decade

Stefan Sleijfer

Stefan Sleijfer's Hit Papers

Peers

Countries citing papers authored by Stefan Sleijfer

Fields of papers citing papers by Stefan Sleijfer

All Works

About Stefan Sleijfer

Explore authors with similar magnitude of impact

Papers in